This is the journey of the Relieve Study - a non-interventional, multinational, prospective cohort study. With questions sent in from Lundbeck listeners around the globe – from Switzerland to South East Asia, Egypt to Brazil - host’s Hongye Ren, HEOR Lead at Lundbeck, and Dr. Gregory Mattingly, MD, share some fascinating insights from the Relieve Study, highlighting why the study is reflective of real-world experience of Brintellix® and therefore of meaningful change for patients with MDD    Key Takeaways:  [1:30] Overview of the journey of the Relieve Study.  [2:50]  An explanation of how and why the Relieve study came about.   [3:49] Why there is a need to determine the real-world effect of Vortioxetine.   [8:30] How has the Relieve study showed the short-term and long-term effectiveness of vortioxetine, and why this was such a success?   [5:15] How were the cognitive symptoms measured in the Relieve Study?   [6:10] What value does Brintellix bring to the patients seen from the perspective of Dr. Mattingly’s clinical practices?   [7:25] Are there any differences in the doses of Vortioxetine being used across 1st, 2nd or 3rd line, across different population in different countries or body sizes?   [7:25] Comorbidities: How did patients with MDD comorbid with GAD respond in the Relieve Study?   [9:19] How patients with comorbidities responded in a very similar way to those patients in the study without.   [10:10] The exclusion criteria of the Relieve Study.   [11:35] Dr. Mattingly’s takes on the exclusion criteria of Relieve Study and how this was actuated in real world settings, as well as in the clinical trials.   [13:00] Why this Relieve Study is crucial for HCP’s and their patients?   [14:50] Results: Presenteeism in patients improvement from baseline to week 24.  [15:34] Was there a difference in results in patients that initiating treatment with vortioxetine versus those that switching from another antidepressant present?  [17:28] Greater improvement has been seen associated with earlier use of Vortioxetine.   [17:45] Dr. Mattingly talks about the important clinical messages to bear in mind as we come out of the pandemic.    Resources:  Brintellix Podcast 

Ver todos los episodios